FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895827445> ?p ?o ?g. }

• W2895827445 endingPage "509" @default.
• W2895827445 startingPage "502" @default.
• W2895827445 abstract "Our aim was to study the impact of sex on anticoagulant treatment outcomes during percutaneous coronary intervention in acute myocardial infarction patients.This study was a prespecified analysis of the Bivalirudin versus Heparin in ST-Segment and Non ST-Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated according to Recommended Therapies Registry Trial (VALIDATE-SWEDEHEART) trial, in which patients with myocardial infarction were randomised to bivalirudin or unfractionated heparin during percutaneous coronary intervention. The primary outcome was the composite of death, myocardial infarction or major bleeding at 180 days.There was a lower risk of the primary outcome in women assigned to bivalirudin than to unfractionated heparin (13.6% vs 17.1%, hazard ratio 0.78, 95% confidence interval (0.60-1.00)) with no significant difference in men (11.8% vs 11.2%, hazard ratio 1.06 (0.89-1.26), p for interaction 0.05). The observed difference was primarily due to lower risk of major bleeding (Bleeding Academic Research Consortium definition 2, 3 or 5) associated with bivalirudin in women (8.9% vs 11.8%, hazard ratio 0.74 (0.54-1.01)) but not in men (8.5% vs 7.3%, hazard ratio 1.16 (0.94-1.43) in men, p for interaction 0.02). Conversely, no significant difference in the risk of Bleeding Academic Research Consortium 3 or 5 bleeding, associated with bivalirudin, was found in women 4.5% vs 5.4% (hazard ratio 0.84 (0.54-1.31)) or men 2.9% vs 2.1% (hazard ratio 1.36 (0.93-1.99)). Bleeding Academic Research Consortium 2 bleeding occurred significantly less often in women assigned to bivalirudin than to unfractionated heparin. The risk of death or myocardial infarction did not significantly differ between randomised treatments in men or women.In women, bivalirudin was associated with a lower risk of adverse outcomes, compared to unfractionated heparin, primarily due to a significant reduction in Bleeding Academic Research Consortium 2 bleeds." @default.
• W2895827445 created "2018-10-26" @default.
• W2895827445 creator A5007515859 @default.
• W2895827445 creator A5015768545 @default.
• W2895827445 creator A5018578282 @default.
• W2895827445 creator A5023076001 @default.
• W2895827445 creator A5040799356 @default.
• W2895827445 creator A5041040472 @default.
• W2895827445 creator A5045986754 @default.
• W2895827445 creator A5051178773 @default.
• W2895827445 creator A5058726775 @default.
• W2895827445 creator A5073596004 @default.
• W2895827445 creator A5077055608 @default.
• W2895827445 creator A5079991822 @default.
• W2895827445 date "2018-10-23" @default.
• W2895827445 modified "2023-10-18" @default.
• W2895827445 title "Sex-related response to bivalirudin and unfractionated heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A subgroup analysis of the VALIDATE-SWEDEHEART trial" @default.
• W2895827445 cites W1278248171 @default.
• W2895827445 cites W1473004 @default.
• W2895827445 cites W1602062668 @default.
• W2895827445 cites W1969228218 @default.
• W2895827445 cites W198941496 @default.
• W2895827445 cites W2016463307 @default.
• W2895827445 cites W2044510816 @default.
• W2895827445 cites W2078904498 @default.
• W2895827445 cites W2099409915 @default.
• W2895827445 cites W2114758846 @default.
• W2895827445 cites W2125869734 @default.
• W2895827445 cites W2134124835 @default.
• W2895827445 cites W2156927593 @default.
• W2895827445 cites W2240571907 @default.
• W2895827445 cites W22714619 @default.
• W2895827445 cites W2550836649 @default.
• W2895827445 cites W2599680869 @default.
• W2895827445 cites W2745712984 @default.
• W2895827445 cites W2754054868 @default.
• W2895827445 cites W2775082339 @default.
• W2895827445 doi "https://doi.org/10.1177/2048872618803760" @default.
• W2895827445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30351167" @default.
• W2895827445 hasPublicationYear "2018" @default.
• W2895827445 type Work @default.
• W2895827445 sameAs 2895827445 @default.
• W2895827445 citedByCount "7" @default.
• W2895827445 countsByYear W28958274452018 @default.
• W2895827445 countsByYear W28958274452019 @default.
• W2895827445 countsByYear W28958274452020 @default.
• W2895827445 countsByYear W28958274452021 @default.
• W2895827445 countsByYear W28958274452023 @default.
• W2895827445 crossrefType "journal-article" @default.
• W2895827445 hasAuthorship W2895827445A5007515859 @default.
• W2895827445 hasAuthorship W2895827445A5015768545 @default.
• W2895827445 hasAuthorship W2895827445A5018578282 @default.
• W2895827445 hasAuthorship W2895827445A5023076001 @default.
• W2895827445 hasAuthorship W2895827445A5040799356 @default.
• W2895827445 hasAuthorship W2895827445A5041040472 @default.
• W2895827445 hasAuthorship W2895827445A5045986754 @default.
• W2895827445 hasAuthorship W2895827445A5051178773 @default.
• W2895827445 hasAuthorship W2895827445A5058726775 @default.
• W2895827445 hasAuthorship W2895827445A5073596004 @default.
• W2895827445 hasAuthorship W2895827445A5077055608 @default.
• W2895827445 hasAuthorship W2895827445A5079991822 @default.
• W2895827445 hasBestOaLocation W28958274451 @default.
• W2895827445 hasConcept C126322002 @default.
• W2895827445 hasConcept C164705383 @default.
• W2895827445 hasConcept C187960798 @default.
• W2895827445 hasConcept C207103383 @default.
• W2895827445 hasConcept C2777557582 @default.
• W2895827445 hasConcept C2777565915 @default.
• W2895827445 hasConcept C2780400711 @default.
• W2895827445 hasConcept C44249647 @default.
• W2895827445 hasConcept C500558357 @default.
• W2895827445 hasConcept C71924100 @default.
• W2895827445 hasConceptScore W2895827445C126322002 @default.
• W2895827445 hasConceptScore W2895827445C164705383 @default.
• W2895827445 hasConceptScore W2895827445C187960798 @default.
• W2895827445 hasConceptScore W2895827445C207103383 @default.
• W2895827445 hasConceptScore W2895827445C2777557582 @default.
• W2895827445 hasConceptScore W2895827445C2777565915 @default.
• W2895827445 hasConceptScore W2895827445C2780400711 @default.
• W2895827445 hasConceptScore W2895827445C44249647 @default.
• W2895827445 hasConceptScore W2895827445C500558357 @default.
• W2895827445 hasConceptScore W2895827445C71924100 @default.
• W2895827445 hasIssue "6" @default.
• W2895827445 hasLocation W28958274451 @default.
• W2895827445 hasLocation W28958274452 @default.
• W2895827445 hasOpenAccess W2895827445 @default.
• W2895827445 hasPrimaryLocation W28958274451 @default.
• W2895827445 hasRelatedWork W1972702180 @default.
• W2895827445 hasRelatedWork W2101065585 @default.
• W2895827445 hasRelatedWork W2375584960 @default.
• W2895827445 hasRelatedWork W2411391849 @default.
• W2895827445 hasRelatedWork W2579156464 @default.
• W2895827445 hasRelatedWork W2782203991 @default.
• W2895827445 hasRelatedWork W2893320569 @default.
• W2895827445 hasRelatedWork W2895827445 @default.
• W2895827445 hasRelatedWork W2918435398 @default.
• W2895827445 hasRelatedWork W3029448752 @default.
• W2895827445 hasVolume "8" @default.

• next